IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event PR Newswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on IDYA
    IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
    6:00a ET May 1 '24 PR Newswire

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

    https://mma.prnewswire.com/media/820568/IDEAYA_Logo.jpg

    RBC Capital Markets Global Healthcare ConferenceTuesday, May 14th, 2024 at 3:05 PM ET

    -- Fireside chat withYujiro S. Hata, Chief Executive Officer, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst

    A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of theIDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

    About IDEAYA Biosciences

    IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

    Investor and Media ContactIDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor Relationsinvestor@ideayabio.com

    https://c212.net/c/img/favicon.png?sn=SF97930&sd=2024-05-01

    View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-may-2024-investor-relations-event-302130345.html

    SOURCE IDEAYA Biosciences, Inc.

    https://rt.newswire.ca/rt.gif?NewsItemId=SF97930&Transmission_Id=202405010600PR_NEWS_USPR_____SF97930&DateId=20240501

    COMTEX_451709321/1005/2024-05-01T06:00:57

    IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing R...
    6:00a ET April 26 '24 PR Newswire
    IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovase...
    10:05a ET April 24 '24 PR Newswire
    IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expans...
    6:00a ET April 22 '24 PR Newswire
    IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing R...
    6:00a ET April 5 '24 PR Newswire
    IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Rel...
    6:00a ET April 1 '24 PR Newswire
    IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combina...
    6:00a ET March 12 '24 PR Newswire
    IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Rel...
    9:56a ET March 5 '24 PR Newswire
    IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Fi...
    6:00a ET February 20 '24 PR Newswire

    Market data provided by News provided by